Keyphrases
Natural Killer Cells
100%
Memory-like
40%
Natural Killer
18%
Cell Response
15%
Clinical Trials
13%
Interleukin-15 (IL-15)
13%
Leukemia
12%
Adoptive Immunotherapy
11%
Human NK Cells
11%
Natural Killer Cell Subsets
10%
Interleukin-12 (IL-12)
8%
Melanoma
8%
CD-8
8%
N-803
8%
CD8+ T Cells
8%
Tumor Targeting
7%
Osteosarcoma
7%
NKp46
7%
Cell Toxicity
6%
Hematopoietic Cell Transplantation
6%
NK Cell Activity
6%
Antitumor Effect
6%
Multidimensional Analysis
5%
Transcriptome
5%
In Cancer
5%
NCR1
5%
Natural Killer Cell Cytotoxicity
5%
Tumoral
5%
Cellular Homeostasis
5%
T-bet
5%
Donor-derived
5%
Cell Transfer
5%
Remission
5%
Relapsed or Refractory Acute Myeloid Leukemia
5%
Cytotoxicity
5%
Clinical Benefit
5%
Effector Cells
5%
Initiating Cells
5%
Malignant Transformation
5%
Interleukin-18 Receptor
5%
Bone Marrow Transplantation
5%
Ultra-deep Sequencing
5%
Canine Sarcoma
5%
Cell-based
5%
Viral Disease
5%
First Responders
5%
Cancer Treatment
5%
Cell Cytokines
5%
Hypersecretion
5%
Cell Localization
5%
Immunology and Microbiology
Natural Killer Cell
90%
Cytokine
19%
Gene Expression
15%
Cytotoxicity
13%
T Cell
11%
Natural Killer Cell Response
10%
Immunotherapy
10%
Cytotoxic T-Cell
9%
CD8
8%
RNA Sequence
8%
Adoptive Immunotherapy
8%
Interleukin 15
7%
Immunocompetent Cell
7%
Interleukin 12
7%
Immunity
6%
Agonist
6%
Transcriptome
6%
Cell Activation
5%
Homeostasis
5%
Mouse Model
5%
Reed Sternberg Cell
5%
Eomesodermin
5%
Cell Transplantation
5%
Interleukin-18 Receptor
5%
Neck
5%
T Cell Receptor
5%
Whole Exome Sequencing
5%
Rituximab
5%
Hematopoietic Cell
5%
Chimeric Antigen Receptor
5%
Borrelia burgdorferi
5%
Physical Performance
5%
Cell Cycle
5%
Insulin Resistance
5%
Transcriptomics
5%
Db/Db Mouse
5%
Long Term Survival
5%
Immunology
5%
Medicine and Dentistry
Natural Killer Cell
63%
Natural Killer Cell Response
10%
Immunotherapy
9%
Malignant Neoplasm
8%
Adoptive Immunotherapy
8%
Cytotoxicity
8%
Cell Therapy
7%
Acute Myeloid Leukemia
7%
Cell Transplantation
7%
Hematopoietic Cell
7%
Receptor
6%
CD8 Antigen
6%
Leukemia
5%
Homeostasis
5%
Patient with Leukemia
5%
Eomesodermin
5%
Transplantation
5%
Classical Hodgkin Lymphoma
5%
Chimeric Antigen Receptor
5%
Pediatrics Patient
5%
Head and Neck Squamous Cell Carcinoma
5%
Head and Neck Cancer
5%
Tumor Differentiation
5%
Rituximab
5%
Non-Hodgkin Lymphoma
5%
Melanoma
5%
Colorectal Carcinoma
5%
Cell Activation
5%
Immunology
5%
